Intralesional TTI-621 in Patients With Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Haematology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study
Lancet Haematol 2021 Nov 01;8(11)e808-e817, C Querfeld, JA Thompson, MH Taylor, JA DeSimone, JM Zain, AR Shustov, C Johns, S McCann, GHY Lin, PS Petrova, RA Uger, N Molloy, Y Shou, OE AkilovFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.